Clinical Trials

24 enrolled

Lymphoid

Hodgkin Disease

NCT05955261 2026-04-13

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled

Leukemia, Myeloid, Acute

NCT06504459 2026-04-13

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03466294 2026-04-09

Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML

42 enrolled 9 charts

Leukemia, Myeloid, Acute

NCT05442216 2026-04-08

TAGALONG

53 enrolled

Leukemia, Myeloid, Acute

NCT07514832 2026-04-07

VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

48 enrolled

Leukemia, Myeloid, Acute

NCT07514936 2026-04-07

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

120 enrolled

Leukemia, Myeloid, Acute

NCT02816021 2026-04-06

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

24 enrolled

Dermatologic

Melanoma

NCT04803201 2026-04-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2 Suspended

170 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT07507825 2026-04-02

VHAG

61 enrolled

Leukemia, Myeloid, Acute

NCT01787487 2026-03-31

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

121 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT05376111 2026-03-19

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

LymphoidOther hematologic neoplasm

28 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06220162 2026-03-19

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

32 enrolled

Leukemia, Myeloid, Acute

NCT06379360 2026-03-19

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

77 enrolled

Leukemia, Myeloid, Acute

NCT06557421 2026-03-13

STOP VEN

Leukemia, Myeloid, Acute

NCT07471841 2026-03-13

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

25 enrolled

Leukemia, Myeloid, Acute

NCT07463768 2026-03-11

MIVONU

60 enrolled

Leukemia, Myeloid, Acute

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

75 enrolled 14 charts

Leukemia, Myeloid, Acute

NCT04128501 2026-03-06

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

LymphoidOther hematologic neoplasm

100 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

112 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT07392242 2026-03-06

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

45 enrolled

Leukemia, Myeloid, Acute

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07304011 2026-03-05

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

28 enrolled

Leukemia, Myeloid, Acute

NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

27 enrolled

Myeloid

Accelerated Phase Myeloproliferative Neoplasm

NCT06483906 2026-03-03

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.

56 enrolled

Leukemia, Myeloid, Acute

NCT06511882 2026-02-27

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

37 enrolled

Leukemia, Myeloid, Acute

NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

43 enrolled

Myeloid Malignancy

NCT06773208 2026-02-24

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

30 enrolled

Leukemia, Myeloid, Acute

NCT03383575 2026-02-17

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Classical hematologyOther hematologic neoplasm

63 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

MyeloidOther hematologic neoplasm

206 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03264404 2026-01-27

Azacitidine and Pembrolizumab in Pancreatic Cancer

36 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04891068 2026-01-14

BRE-04

Breast

Breast Neoplasms

NCT04062266 2026-01-13

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Hematologic Diseases, Leukemia, Myeloid, Acute

NCT05317000 2026-01-12

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06232655 2025-12-19

Cladribine Venetoclax in Monocytic AML

20 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT05074355 2025-12-18

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

Myeloid

Myeloproliferative Disorders

NCT07276698 2025-12-11

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

39 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT01869114 2025-12-10

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

57 enrolled 13 charts

Chromosome 5q Deletion Syndrome, Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT05361057 2025-12-05

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Phase 2 Terminated

20 enrolled

Leukemia, Myeloid, Acute

NCT05566054 2025-11-21

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

92 enrolled

Leukemia, Monocytic, Acute

NCT06451861 2025-11-17

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

240 enrolled

Leukemia, Myeloid, Acute

NCT04801797 2025-11-14

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

172 enrolled

Leukemia, Myeloid, Acute

NCT03586609 2025-10-10

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

145 enrolled

Leukemia, Myeloid, Acute

NCT06668558 2025-09-19

VERDI

29 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05305859 2025-09-11

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

30 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT07159620 2025-09-08

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

LymphoidOther hematologic neoplasm

27 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06429098 2025-09-04

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Leukemia, Myeloid, Acute

NCT03769532 2025-08-24

PEMAZA

Phase 2 Terminated

26 enrolled